"Antifungal Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Substances that destroy fungi by suppressing their ability to grow or reproduce. They differ from FUNGICIDES, INDUSTRIAL because they defend against fungi present in human or animal tissues.
| Descriptor ID |
D000935
|
| MeSH Number(s) |
D27.505.954.122.136
|
| Concept/Terms |
Antifungal Agents- Antifungal Agents
- Agents, Antifungal
- Therapeutic Fungicides
- Fungicides, Therapeutic
|
Below are MeSH descriptors whose meaning is more general than "Antifungal Agents".
Below are MeSH descriptors whose meaning is more specific than "Antifungal Agents".
This graph shows the total number of publications written about "Antifungal Agents" by people in this website by year, and whether "Antifungal Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 2 | 0 | 2 |
| 2003 | 2 | 1 | 3 |
| 2004 | 3 | 1 | 4 |
| 2005 | 3 | 2 | 5 |
| 2006 | 2 | 2 | 4 |
| 2007 | 2 | 0 | 2 |
| 2008 | 1 | 1 | 2 |
| 2009 | 1 | 2 | 3 |
| 2010 | 2 | 1 | 3 |
| 2011 | 0 | 1 | 1 |
| 2012 | 0 | 3 | 3 |
| 2013 | 3 | 4 | 7 |
| 2014 | 1 | 0 | 1 |
| 2015 | 0 | 1 | 1 |
| 2016 | 1 | 0 | 1 |
| 2018 | 2 | 0 | 2 |
| 2019 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antifungal Agents" by people in Profiles.
-
Yano J, Sobel JD, Nyirjesy P, Sobel R, Williams VL, Yu Q, Noverr MC, Fidel PL. Current patient perspectives of vulvovaginal candidiasis: incidence, symptoms, management and post-treatment outcomes. BMC Womens Health. 2019 03 29; 19(1):48.
-
Crouss T, Sobel JD, Smith K, Nyirjesy P. Long-Term Outcomes of Women With Recurrent Vulvovaginal Candidiasis After a Course of Maintenance Antifungal Therapy. J Low Genit Tract Dis. 2018 Oct; 22(4):382-386.
-
Brand SR, Degenhardt TP, Person K, Sobel JD, Nyirjesy P, Schotzinger RJ, Tavakkol A. A phase 2, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of orally administered VT-1161 in the treatment of recurrent vulvovaginal candidiasis. Am J Obstet Gynecol. 2018 06; 218(6):624.e1-624.e9.
-
Powell AM, Gracely E, Nyirjesy P. Non-albicans Candida Vulvovaginitis: Treatment Experience at a Tertiary Care Vaginitis Center. J Low Genit Tract Dis. 2016 Jan; 20(1):85-9.
-
Satlin MJ, Vardhana S, Soave R, Shore TB, Mark TM, Jacobs SE, Walsh TJ, Gergis U. Impact of Prophylactic Levofloxacin on Rates of Bloodstream Infection and Fever in Neutropenic Patients with Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2015 Oct; 21(10):1808-14.
-
Whaley SG, Caudle KE, Vermitsky JP, Chadwick SG, Toner G, Barker KS, Gygax SE, Rogers PD. UPC2A is required for high-level azole antifungal resistance in Candida glabrata. Antimicrob Agents Chemother. 2014 Aug; 58(8):4543-54.
-
Maron GM, Hayden RT, Rodriguez A, Rubnitz JE, Flynn PM, Shenep JL, Knapp KM. Voriconazole prophylaxis in children with cancer: changing outcomes and epidemiology of fungal infections. Pediatr Infect Dis J. 2013 Dec; 32(12):e451-5.
-
Gallo-Ebert C, Donigan M, Stroke IL, Swanson RN, Manners MT, Francisco J, Toner G, Gallagher D, Huang CY, Gygax SE, Webb M, Nickels JT. Novel antifungal drug discovery based on targeting pathways regulating the fungus-conserved Upc2 transcription factor. Antimicrob Agents Chemother. 2014; 58(1):258-66.
-
Steier Z, Vermitsky JP, Toner G, Gygax SE, Edlind T, Katiyar S. Flucytosine antagonism of azole activity versus Candida glabrata: role of transcription factor Pdr1 and multidrug transporter Cdr1. Antimicrob Agents Chemother. 2013 Nov; 57(11):5543-7.
-
Bhardwaj H, Bhardwaj B, Levin DC, Carlile PV. An unusual case of pulmonary coccidioidomycosis presenting as pneumothorax. J Okla State Med Assoc. 2013 Aug; 106(8):315, 317-8.